AI assistant
Verastem, Inc. — Director's Dealing 2025
May 21, 2025
32713_dirs_2025-05-20_18c889f8-8992-4056-b6e2-56530ba08aa3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Verastem, Inc. (VSTM)
CIK: 0001526119
Period of Report: 2025-05-16
Reporting Person: Calkins Daniel (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-05-16 | Common Stock | A | 38850 | $0.00 | Disposed | 125198 | Direct |
| 2025-05-20 | Common Stock | S | 11143 | $8.13 | Disposed | 114055 | Direct |
Footnotes
F1: The reported securities were subject to a performance RSU award that was granted on June 18, 2024. 150,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the FDA of an NDA for the Company's combination therapy of avutometinib and defactinib for the treatment of low-grade serous ovarian cancer had occurred.
F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.